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acinetobacters to imipenem decreased from 96% to 35%
in a decade, although amikacin retained its effectiveness,
susceptibility ranging from 83% to 65%. For P. aeroginosa,
susceptibility to imipenem was 88% in Phase I, 63% in Phase
II, 42% in Phase III and 83% in Phase IV. The corresponding
rates of susceptibility to ceftazidine were 81%, 50%, 67%
and 87%; and that to amikacin were 98%, 97%, 70% and 91%.
Susceptibility of inducible enterobacteriaceae to all ranges
of antibiotics was retained, all isolates were sensitive to
imipenem and ciproﬂoxacin, gentamicin and amikacin in the
last phase. Resistance to ceftazidine in Klebsiella and E. coli
was frequent in the ﬁrst two phases and was predominantly
due to EBSL production. The incidence of EBSL producing
Klebsiella spp and E. coli was variable over the 4 phases,
showing a decrease in the last two phases for EBSL produc-
ing Klebsiella and an absence in the third phase for the EBSL
producing E. coli.
Conclusion: The above ﬁndings will have a signiﬁcant
impact on the empiric treatment of sepsis in critically ill
patients. Emerging problems of multiresistance in P. aerogi-
nosa and Acinetobacters and the growing threat of EBSL
producing organisms in Malaysian hospitals is of concern to
all and calls for a concerted effort towards the control of
emergence and spread of antimicrobial resistance.
doi:10.1016/j.ijid.2008.05.952
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Background: Enterobacteriaceae with reduced suscepti-
bility to third-generation cephalosporin is common at our
institution accounting for about 39% of all Enterobacteri-
aceae isolated. The purpose of this study is to determine
the species, antibiotic susceptibility patterns, and the geno-
typic characterisation of resistance in Enterobacteriaceae
present in patients at the time of presentation to hospital.
Methods: Stool and rectal swab specimens from adult
patients presenting to the Emergency Department and
subsequently hospitalised were screened for Enterobacte-
riaceae with reduced susceptibility by culturing on agar
containing third-generation cephalosporins. The Enterobac-
teriaceae were identiﬁed and antimicrobial susceptibility
tested by conventional methods. The presence of extended-
spectrum beta-lactamase (ESBL) and AmpC beta-lactamase
was screened using double-disc synergy and resistance to
cefoxitin respectively. Multiplex polymerase chain reaction
(PCR) assays for detection of CTX-M and plasmid AmpC genes
were performed on representative isolates according to pub-
lished protocols.
Results: Two hundred twenty-seven isolates of Enter-
obacteriaceae with decreased susceptibility to 3rd gen-
eration cephalosporin were obtained from 1003 patients,
some patients carrying multiple isolates. These isolates
have decreased susceptibility to gentamicin (19%) and
ciproﬂoxacin (42%). Of the 135 isolates tested for CTX-
M multiplex PCR, 98 (72.6%) carried the CTX-M gene, of
which 89 (66%) belonged to CTX-M group 1 and 43 (32%)
to CTX-M group 9. Of the 68 isolates tested for AmpC
genes, 51 (75%) were positive, of which 39 (57%) carried the
CMY-2 gene.
Conclusions: The data from our institution showed that
Enterobacteriaceae with reduced susceptibility to 3rd gen-
eration cephalosporins is prevalent in patients presenting
for admission to the Emergency Department. CTX-M ESBL
appears to be the predominant ESBL in this group of iso-
lates. Multidrug-resistant Enterobacteriaceae is also present
in signiﬁcant numbers. Further work is needed to conﬁrm
the presence and to determine the epidemiology of ESBL-
producing Enterobacteriaceae in the community.
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Background of this study: Surgical site infection (SSI) is
still a serious complication after cardiac surgery. This study
was performed to evaluate a new microbial sealant to pre-
vent surgical site infection in patients undergoing cardiac
surgery.
Material and Methods: Between March 2006 and Novem-
ber 2007, 378 patients underwent cardiac surgery at our
institute by a single surgeon. Two patient groups were def-
inited. The standard institutional preoperative preparation
was performed in 189 patients (control group) whether 189
patients received additionally a microbial sealant (Inte-
guSeal group). Both groups were evaluated by patients
characteristics and evaluated by a pre-operative and intra-
operative risk scores. End-point of this study was freedom
of SSI.
Results: Follow up was 100% completed. A signiﬁcant
higher rate of carotid artery disease (p < 0.015), previous
valve replacement (p < 0.001) and bilateral internal mam-
mary artery use (p < 0.002) was seen at the InteguSeal group.
The values of the pre-operative risk factor to develop SSI
was 10.3± 1.7% and 10.0± 1.5% (p = 0.070) for respectively
the control group and the InteguSeal group. The predic-
tion to develop a SSI due to the combinated-operative risk
score was signiﬁcantly higher (p < 0.001) in the InteguSeal
group compared with the control group, namely 9.1± 1.0%
vs. 8.7± 0.8%.
The clinical end-point, however showed a signiﬁcant
decrease of SSI in the InteguSeal group 1.1% (n = 2) compared
